Biotech Fund Trims Nuvalent Stake After 29% Stock Surge

Commodore Capital reduces its position in the cancer drug developer as the stock outperforms the broader market.

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

Commodore Capital, a biotech-focused investment fund, reported selling 850,000 shares of Nuvalent (NASDAQ:NUVL) in the fourth quarter of 2025, reducing its stake from 9.26% to 3.68% of the fund's total assets under management. The estimated value of the share sale was $83.81 million, as Nuvalent's stock price rose 29% over the previous year, outpacing the S&P 500's 13% gain.

Why it matters

The sale highlights the volatility and risk-reward dynamics in the biotech sector, where investors may choose to trim positions in high-flying stocks to reallocate capital, even as the underlying company continues to make progress with its drug development pipeline. Nuvalent's stock performance and the fund's trading activity provide insights into investor sentiment around the company's future prospects.

The details

According to the SEC filing, Commodore Capital sold 850,000 shares of Nuvalent, reducing its stake in the company from 9.26% to 3.68% of the fund's total assets under management. The estimated value of the share sale was $83.81 million, based on Nuvalent's average closing price during the fourth quarter of 2025. The fund's overall position in Nuvalent declined by $65.75 million, factoring in both the trading activity and price changes.

  • Commodore Capital reported the share sale in an SEC filing dated February 17, 2026.
  • The share sale occurred during the fourth quarter of 2025.

The players

Commodore Capital

A biotech-focused investment fund that previously held a significant stake in Nuvalent.

Nuvalent, Inc.

A Cambridge-based biotechnology company specializing in the discovery and development of precision therapies for cancer, with lead product candidates NVL-520 and NVL-655 currently in early-stage clinical trials.

Got photos? Submit your photos here. ›

What’s next

Nuvalent has several upcoming regulatory milestones, including the FDA's acceptance of its NDA for zidesamtinib in ROS1 positive non-small cell lung cancer, with a PDUFA date set for September 18, 2026, and a planned ALK program filing in the first half of 2026.

The takeaway

The Nuvalent sale by Commodore Capital highlights the volatility and risk-reward dynamics in the biotech sector, where investors may choose to trim positions in high-performing stocks to reallocate capital, even as the underlying company continues to make progress with its drug development pipeline. Investors should focus on Nuvalent's ability to convert its regulatory momentum into successful commercial execution and sustain growth beyond its initial product launch.